Literature DB >> 9085397

The cost-effectiveness of the nicotine transdermal patch for smoking cessation.

M A Wasley1, S E McNagny, V L Phillips, J S Ahluwalia.   

Abstract

BACKGROUND: Smoking is the single most preventable cause of premature mortality in the United States. In 13 double-blind, controlled trials, the nicotine transdermal patch has been demonstrated to be an effective aid to quitting smoking, even after 6 months of follow-up. Because physicians and payers may consider the cost of the patch to be prohibitive, we examine the cost-effectiveness of the nicotine patch as an adjunct to brief physician counseling during routine office visits.
METHODS: We estimate the effectiveness of both patch use with brief counseling and counseling alone from meta-analysis of clinical trials. Benefits are measured in terms of years of life gained by those who quit, discounted at 5%. Costs include physician time and patch prescriptions. The incremental cost-effectiveness is quantified as cost per additional year of life saved when patch plus counseling is compared with brief physician counseling alone.
RESULTS: Depending on age, the average costs per year of life saved range from $965 to $1,585 for men and from $1,634 to $2,360 for women. Incremental costs per year of life saved range from $1,796 to $2,949 for men and from $3,040 to $4,391 for women.
CONCLUSION: The nicotine patch is cost-effective and less costly per year of life saved than other widely accepted medical practices. Physicians and third-party payers should recommend the nicotine patch to patients who wish to stop smoking.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9085397     DOI: 10.1006/pmed.1996.0127

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  21 in total

Review 1.  The cost-effectiveness of substance abuse treatment.

Authors:  P G Barnett
Journal:  Curr Psychiatry Rep       Date:  1999-12       Impact factor: 5.285

2.  Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority.

Authors:  S Parrott; C Godfrey; M Raw; R West; A McNeill
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

Review 3.  The limited incorporation of economic analyses in clinical practice guidelines.

Authors:  Joel F Wallace; Scott R Weingarten; Chiun-Fang Chiou; James M Henning; Andriana A Hohlbauch; Margaret S Richards; Nicole S Herzog; Lior S Lewensztain; Joshua J Ofman
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

Review 4.  Pharmacoeconomic considerations in the management of smoking cessation.

Authors:  Christine Godfrey; Godfrey Fowler
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles.

Authors:  A R Gilbert; C Pinget; P Bovet; J Cornuz; C Shamlaye; F Paccaud
Journal:  Tob Control       Date:  2004-06       Impact factor: 7.552

6.  The health benefits of smoking cessation for adult smokers and for pregnant women in Taiwan.

Authors:  C P Wen; T Y Cheng; C-L Lin; H-N Wu; D T Levy; L-K Chen; C-C Hsu; M P Eriksen; H-J Yang; S P Tsai
Journal:  Tob Control       Date:  2005-06       Impact factor: 7.552

7.  Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison.

Authors:  J Cornuz; A Gilbert; C Pinget; P McDonald; K Slama; E Salto; F Paccaud
Journal:  Tob Control       Date:  2006-06       Impact factor: 7.552

8.  Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment.

Authors:  D F Heitjan; D A Asch; Riju Ray; Margaret Rukstalis; Freda Patterson; C Lerman
Journal:  Pharmacogenomics J       Date:  2008-03-18       Impact factor: 3.550

Review 9.  Over-the-counter nicotine replacement therapy: can its impact on smoking cessation be enhanced?

Authors:  Nancy Amodei; R J Lamb
Journal:  Psychol Addict Behav       Date:  2008-12

Review 10.  Cost-effectiveness of smoking cessation and the implications for COPD.

Authors:  Michele A Faulkner; Tom L Lenz; Julie A Stading
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.